BCAX as reported
- Net Income
- −$185M
Net Income · +81% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$135M
Free Cash Flow · +34% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.10
EPS · −170% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$185M | +81% | Q2 2026 |
| EPS | −$3.10 | −170% | Q2 2026 |
| ROE | −34% | n/a | Q2 2026 |
| ROA | −31% | n/a | Q2 2026 |
| Free Cash Flow | −$135M | +34% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Bicara Therapeutics Inc. (BCAX) - Net IncomeNet IncomeBicara Therapeutics Inc. (BCAX)
Biotechnology
Ranks #23 of 145 by Smart Score